Q2 2026 delivered 6% revenue growth and a 56% increase in non-GAAP EPS, driven by strong U.S. and international spine and trauma performance. Adjusted gross margin expanded to 69.4%, and full-year EPS guidance was raised, with continued focus on product innovation and integration of recent acquisit…
Q2 2026 delivered 6% revenue growth and a 56% increase in non-GAAP EPS, driven by strong U.S. and international spine and trauma performance. Adjusted gross margin expanded to 69.4%, and full-year EPS guidance was raised, with continued focus on product innovation and integration of recent acquisitions.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
